Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria  by Facciuto, Marcelo E. et al.
ORIGINAL ARTICLE
Surgical dilemma: liver resection or liver transplantation for
hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in
patients within and outwith Milan criteria
Marcelo E. Facciuto, Caroline Rochon, Mahima Pandey, Manuel Rodriguez-Davalos, Susana Samaniego, David C. Wolf,
Leona Kim-Schluger, Grigory Rozenblit & Patricia A. Sheiner
Liver Transplant and Hepatobiliary Service, Westchester Medical Center, New York Medical College, Valhalla, NY, USA
Abstract
Background: The optimal role of surgery in the management of hepatocellular carcinoma (HCC) is in
continuous evolution.
Objective: The objective of this study was to analyse survival rates after liver resection (LR) and
orthotopic liver transplantation (OLT) for HCC within and outwith Milan criteria in an intention-to-treat
analysis.
Methods: During 1997–2007, 179 patients with cirrhosis and HCC either underwent LR (n = 60) or were
listed for OLT (n = 119). Patients with incidental HCC after OLT, preoperative macrovascular invasion
before LR, non-cirrhosis and Child–Pugh class C cirrhosis prior to OLT were eliminated, leaving 51
patients primarily treated with LR and 106 patients listed for primary OLT (84 of whom were transplanted)
to be included in this analysis. A total of 66 patients fell outwith Milan criteria (26 LR, 40 OLT) and 91
continued to meet Milan criteria (25 LR, 66 OLT).
Results: The median length of follow-up was 26 months. The mean waiting time for OLT was 7 months.
During that time, 21 patients were removed from the waiting list as a result of tumour progression.
Probabilities of dropout were 2% and 13% at 6 and 12 months, respectively, for patients within Milan
criteria, and 34% and 57% at 6 and 12 months, respectively, for patients outwith Milan criteria (P < 0.01).
Tumour size >3 cm was found to be the independent factor associated with dropout (hazard ratio [HR]
6.0). Postoperative survival was slightly higher after OLT, but this was not statistically significant (64% for
OLT vs. 57% for LR). Overall survival from time of listing for OLT or LR did not differ between the two
groups (P = 0.9); for patients within Milan criteria, 1- and 4-year survival rates after LR were 88% and 61%,
respectively, compared with 92% and 62%, respectively, after OLT (P = 0.54). For patients outwith Milan
criteria, 1- and 4-year survival rates after LR were 69% and 54%, respectively, compared with 65% and
40%, respectively, after OLT (P = 0.42). Tumour size >3 cm was again found to be an independent factor
for poor outcome (HR 2.4) in the intention-to-treat analysis.
Conclusions: Survival rates for patients with HCC are similar in LR and OLT. Liver resection can
potentially decrease the dropout rate and serve as a bridge for future salvage LT, particularly in patients
with tumours >3 cm.
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Introduction
Orthotopic liver transplantation (OLT) is the treatment of choice
for patients with Child–Pugh–Turcotte (CPT) class B or C cirrho-
sis and early hepatocellular carcinoma (HCC) (defined by the
Milan group as a solitary HCC of <5 cm, or two or three tumours
measuring <3 cm without gross vascular invasion).1 In patients
with preserved liver function and early HCC, liver resection (LR)
achieves an overall 5-year survival comparable with that of trans-
plantation, with minimal morbidity and mortality. Recurrence of
HCC after LR is expected, and salvage liver transplantation can be
offered for intrahepatic recurrences.2–4
It is increasingly recognized that a significant proportion of
patients who fall outwith the Milan criteria could benefit from
liver transplantation. In a study of patients with HCC >5 cm who
underwent liver transplantation, 5-year survival was 44%.5
Recently, it has been proposed that indications for liver transplan-
tation for HCC be expanded to include a solitary tumour of
<6.5 cm, or three or fewer nodules of which the largest lesion
measures <4.5 cm and a total tumour diameter <8 cm.6
In carefully screened patients with advanced HCC and pre-
served liver function, LR can achieve a 5-year survival rate of
32%.7 However, if we consider the risk for tumour progression
and patient dropout while waiting for OLT, we find that listing for
OLT has a negative impact on patient survival.8
We retrospectively analysed survival after LR and listing for
OLT for patients with HCC within and outwith the Milan criteria
in an intention-to-treat analysis. In addition, we evaluated the
probability of dropout of patients listed for OLT and the applica-
bility of salvage OLT for HCC recurrence after LR.
Materials and methods
All patients with cirrhosis and HCC who were considered for
either LR (with or without subsequent salvage OLT) or primary
OLT between 1997 and 2007 at our institution were evaluated.
Data were extracted from database records, hospital and office
charts and included demographics, aetiology of liver disease,
radiological evaluation of liver tumours, hospital course and
outcome. Liver function was estimated according to CPT classifi-
cation9 and an assessment of portal hypertension, the latter
defined by the presence of varices, a platelet count <100 000/mm,
or a porto-systemic gradient >10 mmHg. Hepatocellular carci-
noma was diagnosed on the basis of standard clinical and imaging
criteria, a-fetoprotein levels (AFP) and biopsy. Routine biopsies
were not performed. Preoperative radiological tumour stage was
based on two abdominal imaging studies, including computed
tomography (CT) or magnetic resonance imaging (MRI). The
presence of extrahepatic metastases was excluded before LR or
OLT based on chest and abdominal CT or MRI, as well as bone
scintigraphy performed within 6 months of surgery.
Tumour-based contraindications for either LR or OLT included
the presence of extrahepatic disease or macroscopic vascular
invasion. Patients with diffuse infiltrating HCC were excluded, as
were patients with regional lymph node involvement discovered at
surgery (Stage IV B; Table 1).
Patients with incidental HCC after OLT, preoperative mac-
rovascular invasion before LR, non-cirrhosis and Child–Pugh
class C cirrhosis prior to OLT were eliminated, leaving 157
patients to be included in this analysis.
Liver resection was offered as initial treatment when patients
had resectable disease and adequate estimated post-resection liver
function reserve.10 Patients listed for OLT were considered for
neoadjuvant anti-tumoral procedures to prevent tumour progres-
sion, including a combination of chemoembolization, percutane-
ous ethanol injection and radiofrequency ablation. Tumours were
staged on the basis of radiological evaluation of the liver and
according to the American Liver Tumor Study Group’s (ALTSG)
modified tumour–node–metastasis (TNM) classification11
(Table 1). Macroscopic vascular invasion was defined as invasion
of the branches of the main portal vein (right or left, not including
sectoral branches) or of one or more of the three hepatic veins
(right, middle or left). Multiple tumours included satellitosis,
multifocal tumours and intrahepatic metastasis.12 Non-tumorous
liver was analysed using the fibrosis classification scheme pro-
posed by Ishak et al.13 Postoperative immunosuppressive therapy
after OLT consisted of a triple-drug regimen of cyclosporine or
tacrolimus, in combination with corticosteroids and mycopheno-
late mofetil. The dose of corticosteroids was gradually tapered
to discontinuation at 3–6 months after OLT. All patients were
Table 1 Staging classification for hepatocellular carcinoma based on
American Liver Tumor Study Group (ALTSG) criteria
Modified tumour–node–metastasis (TNM) staging classification
T0 Tumour not found
T1 One nodule <1.9 cm
T2 One nodule 2.0–5.0 cm
Two or three nodules, all <3.0 cm
T3 One nodule >5.0 cm
Two or three nodules, at least one >3.0 cm
T4a Four or more nodules
T4b One or more nodules plus gross intrahepatic portal
or hepatic vein involvement as indicated by
computed tomography, magnetic resonance
imaging or ultrasound
N1 Any regional (porta hepatis) nodes involved
M1 Any metastatic disease, including extrahepatic portal
or hepatic vein involvement
Stage I T1
Stage II T2
Stage III T3
Stage IVA1 T4a
Stage IVA2 T4b
Stage IV B Any N1, any M1
HPB 399
HPB 2009, 11, 398–404 © 2009 International Hepato-Pancreato-Biliary Association
followed after surgery with CT scans of the chest and abdomen
every 3 months for the first 2 years and every 6 months thereafter.
The AFP level was measured every 3 months. Additional imaging
techniques (MRI, bone scintigraphy) were performed if recurrent
HCC was suspected. Patients with HCC recurrence after LR were
considered for salvage OLT if HCC recurred at an early stage
(ALTSG stage I–II). Patients with extrahepatic recurrence,
advanced hepatic recurrence, a short disease-free interval or a
deteriorating medical condition were excluded from salvage OLT.
Descriptive statistics are expressed as means (standard devia-
tion [SD]) or medians. Chi-square test or Fisher’s test, as appro-
priate, were used for univariate comparisons. Dropout was
defined as removal from the waiting list as a result of exclusion or
death before OLT. Probability curves for dropout were calculated
according to the Kaplan–Meier method. In the analysis of dropout
probability, patient dropout was considered as an event, whereas
OLT was considered as a censor point. In the intention-to-treat
analysis, survival was calculated from the day of listing for OLT in
the OLT group, or the day of LR in the LR group. For univariate
survival analysis, plots were drawn by the Kaplan–Meier method
and comparisons by the log-rank test. The Cox model in which the
hazard ratio (HR) is determined was applied to evaluate the risk
associated with prognostic variables. Differences were considered
significant at P = 0.05. Perioperative death was included in the
survival analysis. All statistical analyses were performed using
stata 9.2 (StataCorp LP, College Station, TX, USA). Follow-up
data were collected until 1 March 2009.
Results
Our study involved 157 patients. In the LR group, 51 HCC
patients were primarily treated with LR. Eight eventually under-
went salvage OLT; these patients remained in the resection arm. In
the OLT group, 106 patients were listed for primary OLT. Patients’
clinical characteristics are shown in Table 2. The majority of the
patients were male. Mean age was higher in the LR group than the
OLT group. Most patients had hepatitis C (HCV), although hepa-
titis B (HBV) was more common in patients undergoing LR. All
patients had severe fibrosis or cirrhosis (Ishak scores of 5–6, stage
F1). Child–Pugh class A patients predominated in the LR group
and class B patients in the OLT group. Neoadjuvant therapy for
HCC was performed in 63 patients (60%) in the OLT group. In the
OLT group, 33 patients received allografts that met standard
donor criteria, four patients received living donor grafts and 47
patients (56%) received extended criteria donor (ecd) liver
allografts. Ecd organs were more frequently allocated to recipients
who fell outwith the Milan criteria (80% outwith vs. 50% within
Milan criteria; P = 0.007). Liver allografts that did not meet stan-
dard donor criteria (ecd) included those with: donor age >70
years; positive viral serology (HCV); prior donor carcinoma
(brain tumour); donation after cardiac death; steatosis >30%, and
high-risk donor behaviour. Radiological characteristics of the
tumours are summarized in Table 3. Mean largest tumour size and
solitary lesions were greater in the LR group. Tumour stages were
equally distributed between treatment groups based on ALTSG
and the new American Joint Committee on Cancer (AJCC)
staging systems.12
Median follow-up lengths were 26 months (range 1–126
months) for the entire cohort, 24 months (range 1–68 months)
for the LR group, and 28 months (range 1–126 months) for the
OLT patients.
The median interval on the waiting list for OLT was 4 months
(range 1–45 months); mean waiting time for patients within the
Milan criteria was 8 months, whereas that for patients outwith the
Milan criteria was 4 months (P = 0.006). During that time, 21
Table 2 Clinical characteristics of hepatocellular carcinoma patients
undergoing surgical liver resection (LR) or listed for orthotopic liver
transplantation (OLT)
LR OLT P-value
Patients, n 51 106
Mean age, years 63 59 0.01
Male gender, n 44 (86%) 83 (78%) 0.2
Aetiology
Hepatitis B, n 13 (26%) 7 (7%) 0.003
Hepatitis C, n 27 (54%) 71 (67%)
Other, n 10 (20%) 28 (26%)
Child–Pugh score
Median 5 7
Mean 5 7 0.01
MELD (Model for End-stage Liver Disease) score
Median 8 12
Mean 9 13 0.01
Preoperative ablation, n 0 63 (60%)
Table 3 Radiological characteristics of hepatocellular carcinoma
(HCC) patients undergoing surgical liver resection (LR) or listed for
orthotopic liver transplantation (OLT)
LR OLT P-value
Largest tumour, mean, cm (SD) 6 (4.3) 3 (2) <0.001
Nodules, mean, n (SD) 1 (.7) 2 (1.1) 0.003
Milan classification
Within 25 66 0.1
Outwith 26 40
American Joint Committee on Cancer staging
I, n 28 49
II, n 18 52 0.2
III A, n 5 5
Wait time for OLT, mean, months
Within Milan criteria 8 0.006
Outwith Milan criteria 4
Median follow-up, months 24 28 0.16
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patients (20%) were removed from the waiting list for OLT as a
result of tumour progression. The cumulative dropout probabili-
ties at 6, 12 and 24 months were 34%, 57% and 86%, respectively,
for patients outwith the Milan criteria, and 2%, 12% and 58%,
respectively, for patients within the Milan criteria (P < 0.001)
(Fig. 1). Cox’s multivariate analysis found tumour size >3 cm (HR
6.0) to be an independent predictor of dropout. There were no
dropouts among patients waiting for LR.
Survival post-surgery was slightly higher after OLT, but this was
not statistically significant (OLT 64%, LR 57%; P = 0.18) (Table 4).
In the LR group, 21 (41%) patients died, 11 (52%) of HCC recur-
rence and four (19%) of liver failure. In the OLT group, 28 (33%)
patients died, nine (32%) of HCC recurrence and 15 (54%) of
liver graft failure. There was a higher incidence of mortality asso-
ciated with liver graft failure after OLT and a higher incidence of
mortality associated with HCC recurrence after LR (P = 0.04).
The incidence of tumour recurrence was significantly higher in
the LR group (63%) than the OLT group (15%) (P 0.01). In the
LR group, 11 patients with HCC recurrence (22% of the LR group;
34% of the LR patients with HCC recurrence) were considered for
salvage OLT based on HCC recurrence within the standard Milan
criteria and a disease-free interval >6 months. Three patients are
still waiting for salvage OLT and eight patients have been success-
fully transplanted; all eight patients are alive (Fig. 2). A total of 21
patients were not candidates for salvage OLT because of very early
recurrence (<6 months post-LR), the presence of extrahepatic
disease or advanced hepatic disease (outwith Milan criteria for
recurrence).
Overall, survival from the time of listing for OLT or LR did not
differ between the two groups; 1- and 4-year overall survival rates
after LR were 78% and 57%, respectively, compared with 82% and
53%, respectively, after listing for OLT (P = 0.9). In patients within
the Milan criteria, 1- and 4-year survival rates after LR were 88%
and 61%, respectively, compared with 92% and 62%, respectively,
after listing for OLT (P = 0.54). In patients outwith the Milan
criteria, 1- and 4-year survival rates after LR were 69% and 54%,
respectively, compared with 65% and 40%, respectively, after
listing for OLT (P = 0.42) (Fig. 3).
The effects of different variables with potential significance on
longterm outcomes for the entire cohort were evaluated. These
included age, sex, aetiology, MELD (Model for End-stage Liver
Disease) score at LR or listing, type of surgery, tumour size and
number of lesions. On multivariate analysis, only tumour size
>3 cm (P = 0.002, HR 2.4, 95% confidence interval [CI] 1.4–4.0)
and MELD score at LR or listing (P = 0.045, HR 1.05, 95% CI
1.0–1.1) remained independent predictors of adverse longterm
outcome.
Discussion
In this study, we retrospectively evaluated the outcome of patients
with HCC selected for LR or listed for OLT. The purpose of the
study was not to compare two treatment groups, but to ascertain
the outcome of a combined strategy employing LR and OLT.
Several treatment options are available to patients with HCC
and well preserved liver function.14 Liver transplantation is the
treatment of choice for patients with early HCC who have mod-
erate to severe cirrhosis.1 By contrast, the optimal treatment for
patients with early HCC and preserved liver function is the subject
of considerable debate.15 In these patients, a decision analysis
study suggested that resection was more cost-effective than trans-
plantation when the waiting time for transplantation exceeded 9
months.16 Margarit et al. showed that the outcome of salvage OLT
was similar to that of primary OLT.3
There are patients with HCC outwith the Milan criteria for
whom OLT would offer an acceptable outcome, but these are
excluded from this option because of the organ shortage. The
4-year survival outcome of 64% after OLT in the present study is
similar to the 44–75% 5-year survival rate reported recently and
further supports the wider acceptance of transplantation for select
patients with advanced HCC.5,6 However, the current organ
allocation system in the USA means that patients with HCC
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Figure 1 (A) Kaplan–Meier estimates for dropout probability by Milan
criteria. Blue line = patients within the Milan criteria; red line =
patients outwith the Milan criteria. (B) Kaplan–Meier estimates for
dropout probability by size of lesions. Blue line = lesions 3 cm; red
line = lesions >3 cm
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beyond the Milan criteria are very unlikely to receive a deceased
liver in a timely manner.17 Data for patients with HCC falling
within the Milan criteria showed that the increase in waiting times
for LT has resulted in a decrease in 3-year survival rates from 80%
to 60% according to an intent-to-treat analysis, which takes into
account patient dropouts resulting from tumour progression
while waiting.8 Patients with HCC outwith the Milan criteria are
at higher risk for disease progression, which will have a negative
impact on their survival in the OLT arm of an intent-to-treat
analysis. The dropout rate in patients with advanced HCC waiting
for OLT has been reported to be nearly one-third.5 In the present
study, patients outwith the Milan criteria had significantly earlier
and higher rates of dropout caused by progression compared with
patients within the Milan criteria (34% vs. 12% at 6 months). This
difference in risk for dropout is not explained by the increased
waiting times of patients outwith the Milan criteria. In fact, in the
present study, patients whose tumours fell outwith the Milan cri-
teria had shorter waiting times, mainly because of the use of ecd
organs. The critical organ shortage has prompted the reconsidera-
tion of potential donors with positive serology or a history of
malignancy, older donors, or non-heart beating donors.18 In all,
80% of our patients outwith the Milan criteria who underwent
OLT received ecd organs. The rationale behind the use of such
organs is that it can increase opportunities to control the progres-
sion of HCC by improving access to transplantation. Tumour size
>3 cm was the strongest predictor for dropout from the transplant
list and represented a risk that affected not only those patients
who fell outwith the Milan criteria, but also those who fulfilled the
criteria.
As an alternative approach for patients with preserved liver
function, LR has become increasingly safe and can be performed
without delay. Fong et al., reported 3- and 5-year survival rates of
48% and 33%, respectively, for patients with tumours >5 cm.7
These results would indicate that LR has, indeed, a role to play in
the treatment strategy for advanced HCC. Overall cancer recur-
rence after LR generally exceeds 70% at 5 years.3,19,20 Recent series
in patients with early HCC showed that with close follow-up the
majority of hepatic recurrences after resection were detected at an
early tumour stage and the results of salvage OLT were similar to
those of primary OLT.3,21,22 Our study found that a third of
Table 4 Overall survival and hepatocellular carcinoma (HCC) recurrence after liver resection (LR) and orthotopic liver transplantation (OLT)
LR OLT P-value
Overall survival IT
1 year 78% 82%
4 years 57% 53% 0.9
Survival post-surgery
1 year 78% 84% 0.18
4 years 57% 64%
Cause of death
HCC 11/21 (52%) 9/28 (32%)
Liver failure 4 (19%) 15 (54%) 0.04
Other 6 4
Total recurrence 32/51 (63%) 12/84 (15%) <0.001
Type of recurrence
Salvage OLT 11/32 (34%)
Not an OLT candidate 21/32 (66%)
Time to recurrence, median, months
Overall recurrence 8 14 0.18
Salvage OLT 18
Not an OLT candidate 6 0.01
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Figure 2 Kaplan–Meier estimates for survival of patients with recur-
rent hepatocellular carcinoma (HCC) after liver resection by type of
recurrence. Blue line = salvage orthotopic liver transplantation; red
line = HCC recurrence; green line = no recurrence
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patients with HCC recurrence (34%) and a fifth (22%) of the
entire LR group received salvage OLT, which definitely impacted
positively on the longterm survival of patients originally treated
with LR.
When we analysed from time of listing or time of LR in an
intention-to-treat model, we found that the survival of patients
with HCC was similar between LR and OLT. No significant benefit
between LR or OLT was identified in patients who fell within or
outwith the Milan criteria. The strongest independent predictor
for poor outcome was tumour size >3 cm, which represented a
risk shared by patients undergoing LR or OLT, and those within or
outwith the Milan criteria. There seemed to be some equilibrium
between outcomes of the two surgical treatment modalities analy-
sed, in that dropout from the list had a negative impact on overall
OLT survival, and salvage OLT had a positive impact on LR sur-
vival, which made the final outcomes more similar.
In conclusion, LR and OLT are not opposing alternatives, but,
rather, represent the components of a combined strategy for the
management of HCC in cirrhosis. The choice of a particular treat-
ment option should depend upon individual risk factors and the
availability of a donor organ. Liver resection can potentially
improve the survival of patients listed for OLT by decreasing the
risk of dropout, particularly in tumours >3 cm. By contrast, liver
transplantation can prolong survival post-resection and salvage
transplantation can be used in post-resection HCC recurrence.
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